Synthesis and basic evaluation of 7α-(3-[18F]fluoropropyl)-testosterone and 7α-(3-[18F]fluoropropyl)-dihydrotestosterone

被引:0
作者
Okamoto, Mayumi [1 ,2 ,3 ]
Naka, Kyosuke [4 ]
Ishiwata, Kiichi [1 ,5 ,6 ]
Shimizu, Isao [2 ,4 ]
Toyohara, Jun [1 ]
机构
[1] Tokyo Metropolitan Inst Gerontol, Res Team Neuroimaging, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan
[2] Waseda Univ, Res Inst Sci & Engn, Tokyo, Japan
[3] Res Inst Natl Ctr Global Hlth & Med, Dept Pathol & Immunol, Ichikawa, Japan
[4] Waseda Univ, Sch Adv Sci & Engn, Tokyo, Japan
[5] Southern Tohoku Res Inst Neurosci, Inst Cyclotron & Drug Discovery Res, Koriyama, Fukushima, Japan
[6] Fukushima Med Univ, Dept Biofunct Imaging, Fukushima, Japan
关键词
Androgen receptor; 7 alpha-(3-[F-18]Fluoropropyl)-testosterone; 7 alpha-(3-[F-18]Fluoropropyl)-dihydrotestosterone; Positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; HORMONE-BINDING GLOBULIN; PROSTATE-CANCER; ANDROGEN RECEPTOR; TISSUE DISTRIBUTION; IMAGING AGENTS; CYTOCHROME-P450; 2E1; PET; STEROIDS; TUMORS;
D O I
10.1007/s12149-016-1130-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
7 alpha-Substituted androgen derivatives may have the potential to visualize androgen receptors with positron emission tomography. In the present study, we synthesized fluoropropyl derivatives of 7 alpha-(3-[F-18]fluoropropyl)-testosterone ([F-18]7) and 7 alpha-(3-[F-18]fluoropropyl)-dihydrotestosterone ([F-18]15), and characterized their in vitro binding, in vivo biodistribution, and performed blocking studies in mature androgen deprived male rats. We synthesized [F-18]7 and [F-18]15. In vitro binding to recombinant rat AR ligand binding domain protein was determined using a competitive radiometric ligand-binding assay with the high-affinity synthetic androgen [17 alpha-methyl-H-3]-methyltrienolone ([H-3]R1881). In vivo biodistribution was performed in mature male rats treated with diethylstilbestrol (chemical castration). A blocking study was performed by co-administration of dihydrotestosterone (36 A mu g/animal). 7 alpha-(3-Fluoropropyl)-testosterone (7) and 7 alpha-(3-fluoropropyl)-dihydrotestosterone (15) showed competitive binding to recombinant rat AR ligand binding domain protein. The IC50 value of 15 (13.0 +/- 3.3 nM) was higher than 7 (47.8 +/- 10.0 nM). In contrast to the AR binding affinity, the ventral prostate uptake of [F-18]7 and [F-18]15 at 2 h post-injection was similar (0.07 % injected dose/g of tissue). A blocking study indicated that specific binding of [F-18]15 is observed in the ventral prostate. [F-18]7 and [F-18]15 showed moderate levels of bone uptake, which indicates moderate metabolic de-fluorination in rodents. [F-18]15 is better than [F-18]7 in terms of radiochemical yield, in vitro binding affinity, prostate specific binding and stability against in vivo metabolic de-fluorination. However, the net uptake level of [F-18]15 in prostate might be insufficient for in vivo visualization. Although [F-18]7 and [F-18]15 improved in vivo stability against de-fluorination, other basic characterization data in rodents were not superior to the current standard tracer 16 beta-[F-18]fluoro-5 alpha-dihydrotestosterone. It is also revealed that the shorter side chain length of 7 alpha-[F-18]fluoromethyl-dihydrotestosterone is superior to the longer three carbon chain in [F-18]15, in terms of net prostate uptake and in vivo metabolic stability.
引用
收藏
页码:53 / 62
页数:10
相关论文
共 31 条
[1]   First synthesis of separable isomeric testosterone dimers showing differential activities on prostate cancer cells [J].
Bastien, Dominic ;
Leblanc, Valerie ;
Asselin, Eric ;
Berube, Gervais .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (07) :2078-2081
[2]   Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET [J].
Beattie, Bradley J. ;
Smith-Jones, Peter M. ;
Jhanwar, Yuliya S. ;
Schoeder, Heiko ;
Schmidtlein, C. Ross ;
Morris, Michael J. ;
Zanzonico, Pat ;
Squire, Olivia ;
Meirelles, Gustavo S. P. ;
Finn, Ron ;
Namavari, Mohammad ;
Cai, Shangde ;
Scher, Howard I. ;
Larson, Steven M. ;
Humm, John L. .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (02) :183-192
[3]   FUNDAMENTAL CONSIDERATIONS IN THE DESIGN OF F-18 LABELED PROGESTINS AND ANDROGENS AS IMAGING AGENTS FOR RECEPTOR-POSITIVE TUMORS OF THE BREAST AND PROSTATE [J].
BRANDES, SJ ;
KATZENELLENBOGEN, JA .
NUCLEAR MEDICINE AND BIOLOGY, 1988, 15 (01) :53-67
[4]   Mechanisms of resistance in castration-resistant prostate cancer (CRPC) [J].
Chandrasekar, Thenappan ;
Yang, Joy C. ;
Gao, Allen C. ;
Evans, Christopher P. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) :365-380
[5]   SYNTHESIS OF 11-BETA-[F-18]FLUORO-5-ALPHA-DIHYDROTESTOSTERONE AND 11-BETA-[F-18]FLUORO-19-NOR-5-ALPHA-DIHYDROTESTOSTERONE - PREPARATION VIA HALOFLUORINATION-REDUCTION, RECEPTOR-BINDING, AND TISSUE DISTRIBUTION [J].
CHOE, YS ;
LIDSTROM, PJ ;
CHI, DY ;
BONASERA, TA ;
WELCH, MJ ;
KATZENELLENBOGEN, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (05) :816-825
[6]   Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies [J].
Crawford, E. David ;
Higano, Celestia S. ;
Shore, Neal D. ;
Hussain, Maha ;
Petrylak, Daniel P. .
JOURNAL OF UROLOGY, 2015, 194 (06) :1537-1547
[7]   Positron tomographic assessment of androgen receptors in prostatic carcinoma [J].
Dehdashti, F ;
Picus, J ;
Michalski, JM ;
Dence, CS ;
Siegel, BA ;
Katzenellenbogen, JA ;
Welch, MJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (03) :344-350
[8]   [7α-18F]fluoro-17α-methyl-5α-dihydrotestosterone:: a ligand for androgen receptor-mediated imaging of prostate cancer [J].
Garg, PK ;
Labaree, DC ;
Hoyte, RM ;
Hochberg, RB .
NUCLEAR MEDICINE AND BIOLOGY, 2001, 28 (01) :85-90
[9]   Alternative Inhibition of Androgen Receptor Signaling: Peptidomimetic Pyrimidines As Direct Androgen Receptor/Coactivator Disruptors [J].
Gunther, Jillian R. ;
Parent, Alexander A. ;
Katzenellenbogen, John A. .
ACS CHEMICAL BIOLOGY, 2009, 4 (06) :435-440
[10]   PET Imaging of Steroid Receptor Expression in Breast and Prostate Cancer [J].
Hospers, G. A. P. ;
Helmond, F. A. ;
de Vries, E. G. E. ;
Dierckx, R. A. ;
de Vries, E. F. J. .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (28) :3020-3032